Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Jan 9;18(1):7.
doi: 10.1186/s12906-017-2062-z.

Efficacy and safety of curcumin and its combination with boswellic acid in osteoarthritis: a comparative, randomized, double-blind, placebo-controlled study

Armine Haroyan  1   2 , Vahan Mukuchyan  3 , Nana Mkrtchyan  3 , Naira Minasyan  3 , Srbuhi Gasparyan  3 , Aida Sargsyan  3 , Mikael Narimanyan  4 , Areg Hovhannisyan  5
Affiliations
Clinical Trial

Efficacy and safety of curcumin and its combination with boswellic acid in osteoarthritis: a comparative, randomized, double-blind, placebo-controlled study

Armine Haroyan et al. BMC Complement Altern Med. .

Abstract

Background: The aim of this clinical trial was to assess the efficacy and safety of curcuminoid complex extract from turmeric rhizome with turmeric volatile oil (CuraMed®) and its combination with boswellic acid extract from Indian frankincense root (Curamin®) vs placebo for the treatment of 40- to 70-year-old patients with osteoarthritis (OA).

Methods: The effects of CuraMed® 500-mg capsules (333 mg curcuminoids) and Curamin® 500-mg capsules (350 mg curcuminoids and 150 mg boswellic acid) taken orally three times a day for 12 weeks in 201 patients was investigated in a three-arm, parallel-group, randomized, double-blinded, placebo-controlled trial. Primary outcome efficacy measures included OA physical function performance-based tests, the WOMAC recommended index of joint pain, morning stiffness, limitations of physical function, and the patients' global assessment of disease severity.

Results: Favorable effects of both preparations compared to placebo were observed after only 3 months of continuous treatment. A significant effect of Curamin® compared to placebo was observed both in physical performance tests and the WOMAC joint pain index, while superior efficacy of CuraMed vs placebo was observed only in physical performance tests. The effect size compared to placebo was comparable for both treatment groups but was superior in the Curamin® group. The treatments were well tolerated.

Conclusions: Twelve-week use of curcumin complex or its combination with boswellic acid reduces pain-related symptoms in patients with OA. Curcumin in combination with boswellic acid is more effective. Combining Curcuma longa and Boswellia serrata extracts in Curamin® increases the efficacy of OA treatment presumably due to synergistic effects of curcumin and boswellic acid.

Trial registration: This trial is registered at the database www.clinicaltrials.gov . https://clinicaltrials.gov/ct2/show/NCT02390349?term=EuroPharma&rank=1 . Study registration number: NCT02390349 .

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Ethical approval was obtained from the local Ethics Committee (Health Research Ethics Board at the Yerevan Medical State University of Armenia; 96/13; 22.04.2013), which approved all procedures and written informed consent was obtained from all participants.

The study was conducted in accordance with the Declaration of Helsinki and local laws and regulations. All participants gave written informed consent. Approved all procedures and written informed consent was obtained from all participants.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests. Verum and placebo capsules used in the study were donated by the manufacturer Europharma USA Inc. Europharma USA Inc. had no other involvement in the study.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
CONSORT Diagram - participant flow chart. ITT – intention to treat analysis, which includes all patients who completed the tests. DEA – dropouts excluded analysis, which includes only patients who completed all tests during all 3 visits
Fig. 2
Fig. 2
The changes with time in the maximum number of chair stand repetitions possible in a 30-s period at weeks 0, 4, and 12 in the Curamin, CuraMed and placebo treatment groups. Within-group improvements (*p < 0.05, **p < 0.01, ***p < 0.001) in physical performance tests at the end of the study (visit 3) compared to baseline (week 0)
Fig. 3
Fig. 3
The changes with time in a fast-paced walking test timed over 4 × 10 m for a total 40 m at weeks 0, 4, and 12 in the Curamin, CuraMed and placebo treatment groups. Within-group improvements (*p < 0.05, **p < 0.01, ***p < 0.001) in physical performance tests at the end of the study (visit 3) compared to baseline (week 0)
Fig. 4
Fig. 4
The changes with time in the time required to rise from a chair, walk 3 m, turn, and walk back to the chair at weeks 0, 4, and 12 in the Curamin, CuraMedand placebo treatment groups. Within-group improvements (*p < 0.05, **p < 0.01, ***p < 0.001) in physical performance tests at the end of the study (visit 3) compared to baseline (week 0)
Fig. 5
Fig. 5
The changes with time in the time required to ascend and descend a flight of stairs at weeks 0, 4, and 12 in the Curamin, CuraMed and placebo treatment groups. Within-group improvements (*p < 0.05, **p < 0.01, ***p < 0.001) in physical performance tests at the end of the study (visit 3) compared to baseline (week 0)
See this image and copyright information in PMC

References

    1. Aggarwal BB, Gupta SC, Sung B. Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. Br J Pharmacol. 2013;169:1672–1692. doi: 10.1111/bph.12131. - DOI - PMC - PubMed
    1. Nakagawa Y, Mukai S, Yamada S, Matsuoka M, Tarumi E, Hashimoto T, Tamura C, Imaizumi A, Nishihira J, Nakamura T. Short-term effects of highly-bioavailable curcumin for treating knee osteoarthritis: a randomized, double-blind, placebo-controlled prospective study. J Orthop Sci. 2014;19:933–939. doi: 10.1007/s00776-014-0633-0. - DOI - PMC - PubMed
    1. Belcaro G, Cesarone MR, Dugall M, Pellegrini L, Ledda A, Grossi MG, Togni S, Appendino G. Efficacy and safety of Meriva®, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Altern Med Rev. 2010;15:337–344. - PubMed
    1. Belcaro G, Cesarone MR, Dugall M, Pellegrini L, Ledda A, Grossi MG, Togni S, Appendino G. Product-evaluation registry of Meriva®, a curcumin-phosphatidylcholine complex, for the complementary management of osteoarthritis. Panminerva Med. 2010;52:55–62. - PubMed
    1. Chandran B, Goel A. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res. 2012;26:1719–1725. doi: 10.1002/ptr.4639. - DOI - PubMed

Publication types

Associated data

Grants and funding